Expert Opinion on Therapeutic Targets最新文献_第3页

Targeting the serotonin 1B receptor for the treatment of depression and anxiety. 5 -羟色胺1B受体作为治疗抑郁和焦虑的靶点。

IF 5.1 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2026-09-01 Epub Date: 2026-09-28 DOI: 10.1080/14728222.2026.2738183

Sixtine Fleury, Katherine M Nautiyal

{"title":"Targeting the serotonin 1B receptor for the treatment of depression and anxiety.","authors":"Sixtine Fleury, Katherine M Nautiyal","doi":"10.1080/14728222.2026.2738183","DOIUrl":"10.1080/14728222.2026.2738183","url":null,"abstract":"Introduction: Depressive and anxiety disorders impose a substantial public health burden, yet current serotonergic therapies are limited by delayed onset, modest remission rates, and adverse side effects. Here we put forward the serotonin 1B receptor (5-HT1BR) as an important therapeutic target for mood related pathology.Areas covered: We synthesize converging evidence from human and preclinical studies that link 5-HT1BR expression and function to affective phenotypes. Importantly, agonists and the p11 dependent surface trafficking pathway produce antidepressant like effects. Additionally, recent work demonstrates that 5-HT1BR signaling is required for the sustained pro-hedonic and anxiolytic actions of psilocybin. Mechanistically, 5-HT1BR modulates corticolimbic synaptic plasticity and regulates neurotransmitter release from both serotonergic and non-serotonergic terminals, positioning it to reshape dysfunctional neural circuitry. FDA-approved drugs that have 5-HT1BR agonist activity show favorable safety profiles, but there is limited clinical data from brain-penetrant selective ligands.Expert opinion: We propose prioritized research avenues: PET-based occupancy biomarkers, clinical trials with 5-HT1BR agonists, and exploration of sex and stress dependent effects. Additionally, in the recent drive to study and develop novel psychedelic-related compounds, it is important to consider 5-HT1BR activation. Collectively, preclinical evidence supports 5-HT1BR as a tractable, high-impact target poised to contribute to antidepressant strategies.","PeriodicalId":12185,"journal":{"name":"Expert Opinion on Therapeutic Targets","volume":" ","pages":"923-928"},"PeriodicalIF":5.1,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149016029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

ACK family tyrosine kinases as potential therapeutic targets for cancer. ACK家族酪氨酸激酶作为癌症的潜在治疗靶点。

IF 5.1 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2026-08-01 Epub Date: 2026-07-28 DOI: 10.1080/14728222.2026.2709794

Radhika Mittal, Priya Priya, Jyotirmoy Banerjee, Aparna Banerjee Dixit

{"title":"ACK family tyrosine kinases as potential therapeutic targets for cancer.","authors":"Radhika Mittal, Priya Priya, Jyotirmoy Banerjee, Aparna Banerjee Dixit","doi":"10.1080/14728222.2026.2709794","DOIUrl":"10.1080/14728222.2026.2709794","url":null,"abstract":"Introduction: The activated Cdc42-associated kinase (ACK) family, comprising TNK1 and ACK1/TNK2, are critical regulators of oncogenic signaling and epigenetic reprogramming. Their unique structural architecture, including ubiquitin-association domain, sterile alpha motif domain, and Mig6 homology regions, distinguishes them from other non-receptor kinases. ACK1 often, elevated in diverse malignancies, functions as a cytoplasmic transducer and nuclear epigenetic modifier, phosphorylating histones H4 at Tyr88 and H3 at Tyr54 driving cell survival, therapy resistance, and immune evasion. Conversely, TNK1 predominantly operates via ubiquitin‑mediated signaling, P activation, and STAT-dependent pathways in hematological cancers. Hence, understanding these mechanisms is crucial for developing targeted therapeutic strategies.Areas covered: This review comprehensively examines the ACK family architecture, regulation, epigenetic mechanisms, and roles in several malignancies. It evaluates targeted therapies, immunotherapy, and drug development including selective inhibitors, dual agents, and rational combinations.Expert opinion: The unique structure of ACK kinases presents a distinct therapeutic target for selective inhibition. ACK1/TNK2 and TNK1 offer complementary opportunities whose parallel clinical development is scientifically justified and strategically timely. Future research should map the complete ACK family epigenetic framework for biomarker‑driven selection and deeper mechanistic understanding. Clinical development of selective ACK inhibitors will potentially provide new treatment options for difficult-to-treat malignancies.","PeriodicalId":12185,"journal":{"name":"Expert Opinion on Therapeutic Targets","volume":" ","pages":"817-825"},"PeriodicalIF":5.1,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148590987","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Interleukin-6 as a therapeutic target in diabetic macular edema: current evidence and future perspectives. 白细胞介素-6作为糖尿病黄斑水肿的治疗靶点：目前的证据和未来的观点。

IF 5.1 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2026-08-01 Epub Date: 2026-08-18 DOI: 10.1080/14728222.2026.2720412

Hidetaka Noma, Tatsuya Mimura

{"title":"Interleukin-6 as a therapeutic target in diabetic macular edema: current evidence and future perspectives.","authors":"Hidetaka Noma, Tatsuya Mimura","doi":"10.1080/14728222.2026.2720412","DOIUrl":"10.1080/14728222.2026.2720412","url":null,"abstract":"Introduction: Diabetic macular edema (DME) is a major cause of vision loss in diabetic retinopathy. Although anti-vascular endothelial growth factor (VEGF) therapy is the current standard treatment, many patients show incomplete responses, indicating the contribution of VEGF-independent mechanisms. Increasing evidence identifies interleukin-6 (IL-6) as a key mediator of inflammation, blood-retinal barrier disruption, and retinal vascular dysfunction in DME.Areas covered: This review summarizes the biological functions and signaling pathways of IL-6 in DME and examines the clinical relevance of elevated intraocular IL-6 levels. We discuss the crosstalk between IL-6 and VEGF, review current evidence for IL-6-targeting agents, including tocilizumab and sarilumab, and evaluate their therapeutic potential, particularly in treatment-resistant DME.Expert opinion: IL-6 acts as a central hub cytokine linking chronic inflammation, vascular permeability, and retinal microvascular injury. By modulating both VEGF-dependent and VEGF-independent pathways, IL-6 inhibition represents a promising therapeutic strategy for refractory DME. Although direct clinical evidence remains limited, advances in biomarker-guided patient selection, local drug delivery systems, and combination approaches with anti-VEGF therapy may facilitate the development of precision medicine for DME.","PeriodicalId":12185,"journal":{"name":"Expert Opinion on Therapeutic Targets","volume":" ","pages":"839-852"},"PeriodicalIF":5.1,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148759188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

BCAA metabolic reprogramming identifies BCKDK as a therapeutic target in cancer. BCAA代谢重编程确定BCKDK作为癌症的治疗靶点。

IF 5.1 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2026-08-01 Epub Date: 2026-07-30 DOI: 10.1080/14728222.2026.2709804

Zhihan Li, Yuxuan Zhou, Li Zhang, Quanjun Yang

{"title":"BCAA metabolic reprogramming identifies BCKDK as a therapeutic target in cancer.","authors":"Zhihan Li, Yuxuan Zhou, Li Zhang, Quanjun Yang","doi":"10.1080/14728222.2026.2709804","DOIUrl":"10.1080/14728222.2026.2709804","url":null,"abstract":"Introduction: Branched-chain keto acid dehydrogenase kinase (BCKDK) is a mitochondrial kinase that suppresses branched-chain amino acid (BCAA) oxidative catabolism by phosphorylating and inhibiting the branched-chain α-keto acid dehydrogenase complex. Beyond this canonical metabolic function, accumulating evidence indicates that aberrant BCKDK activation contributes to tumor metabolic rewiring, signaling adaptation, malignant progression and therapy resistance.Areas covered: This review summarizes the regulatory position of BCKDK in BCAA catabolism, its context-dependent functions across tumor types, and recent progress in BCKDK inhibitor development. Although selected non-oncological studies are discussed to inform inhibitor mechanism, pharmacology and safety, this review focuses on the oncology relevance of BCKDK. Particular attention is given to the transition from early proof-of-concept inhibitors to BT2-derived allosteric compounds, Pfizer-developed clinical candidates, and emerging non-BT2 scaffolds or alternative binding regions. A PubMed search was conducted to identify relevant studies on BCKDK, BCAA metabolism, cancer progression and BCKDK-targeted inhibitors.Expert opinion: BCKDK is unlikely to function as a universal pan-cancer target. Its therapeutic value will depend on identifying tumor contexts with true BCKDK dependency, especially those relying on BCKDK-driven metabolic adaptation or downstream signaling. For BCKDK inhibitors, future development should integrate biochemical potency with mechanism-aligned conformational effects, long-term pharmacological consequences and biomarker-supported patient stratification.","PeriodicalId":12185,"journal":{"name":"Expert Opinion on Therapeutic Targets","volume":" ","pages":"903-917"},"PeriodicalIF":5.1,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148577608","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Breakthroughs in our molecular understanding of therapeutic targets for pulmonary hypertension. 我们对肺动脉高压治疗靶点的分子认识取得突破。

IF 5.1 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2026-08-01 Epub Date: 2026-07-29 DOI: 10.1080/14728222.2026.2709796

Gerrit Bredeck, Alejandro Cruz-Utrilla, Eduardo Oliver

{"title":"Breakthroughs in our molecular understanding of therapeutic targets for pulmonary hypertension.","authors":"Gerrit Bredeck, Alejandro Cruz-Utrilla, Eduardo Oliver","doi":"10.1080/14728222.2026.2709796","DOIUrl":"10.1080/14728222.2026.2709796","url":null,"abstract":"Introduction: Pulmonary hypertension (PH) is characterized by progressive pulmonary vascular remodeling, rising right-ventricular afterload, and eventual maladaptation, which is a major determinant of prognosis. While established therapies mainly target vasoconstrictive pathways, recent development has shifted toward disease-modifying strategies that address remodeling, inflammation, and metabolic dysfunction in PH patients.Areas covered: This Special Report summarizes selected breakthrough therapeutic targets in PH, focusing on mechanisms supported by strong causal rationale and evaluated in at least Phase II clinical testing. Covered pathways include bone morphogenetic proteins/activin signaling rebalancing, growth factor and kinase inhibition, zinc transport targeting, inflammatory and immune-directed approaches, and metabolic modulation. We emphasize translational relevance, current clinical status, and key challenges limiting broader implementation of these approaches.Expert opinion: The next advance in PH treatment will depend not only on identifying effective targets but also on improving precision in their deployment. Three barriers are especially important: responder heterogeneity, incomplete benefit-risk stratification, and uncertainty about target engagement in vivo. Therefore, biomarker-guided enrichment, integrated safety profiling, and practical pharmacodynamic readouts should become central elements of trial design. In parallel, expansion of the therapeutic toolbox, including stress-sensing, adrenergic, senescence, and hypoxia-related pathways, may increase the likelihood of matching individual patients to effective disease-modifying therapy.","PeriodicalId":12185,"journal":{"name":"Expert Opinion on Therapeutic Targets","volume":" ","pages":"807-816"},"PeriodicalIF":5.1,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148561182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Assessing the preclinical progress in the therapeutic targeting of axial spondyloarthritis. 评估轴型脊柱炎治疗靶向性的临床前进展。

IF 5.1 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2026-08-01 Epub Date: 2026-08-22 DOI: 10.1080/14728222.2026.2722195

Ronan Soudy, Manon Jacoutot, Paul Gervaise, Chiara Bonini, Aida Boukamel, Luiza M Araujo, Félicie Costantino, Simon Glatigny, Maxime Breban

{"title":"Assessing the preclinical progress in the therapeutic targeting of axial spondyloarthritis.","authors":"Ronan Soudy, Manon Jacoutot, Paul Gervaise, Chiara Bonini, Aida Boukamel, Luiza M Araujo, Félicie Costantino, Simon Glatigny, Maxime Breban","doi":"10.1080/14728222.2026.2722195","DOIUrl":"10.1080/14728222.2026.2722195","url":null,"abstract":"Introduction: Axial spondyloarthritis (SpA) is a chronic inflammatory rheumatism affecting predominantly the axial skeleton and frequently also the peripheral joints, often associated with specific extra-musculoskeletal manifestations. This complex disease is still poorly understood resulting in a lack of cure. While symptomatic treatments are available, preclinical models/analyses are needed to identify new therapeutic targets in order to improve axial SpA treatment.Areas covered: We discussed strengths and weaknesses of preclinical models used to identify and validate emerging therapeutic targets.Expert opinion: Progress in developing new therapies for axial SpA remains slow due to its biological complexity and limited understanding of early disease mechanisms. Current treatments mainly target downstream inflammation, contributing to persistent unmet needs and variable responses. Future progress will rely on more pathophysiologically relevant models, interdisciplinary approaches, and integration of insights from related diseases to accelerate personalized therapeutic development.","PeriodicalId":12185,"journal":{"name":"Expert Opinion on Therapeutic Targets","volume":" ","pages":"827-837"},"PeriodicalIF":5.1,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148790127","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hepatic T-cell dysfunction in chronic liver disease and hepatocellular carcinoma: a spatial systems-immunology framework for precision immunotherapy. 慢性肝病和肝细胞癌的肝t细胞功能障碍：精确免疫治疗的空间系统免疫学框架。

IF 5.1 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2026-08-01 Epub Date: 2026-08-26 DOI: 10.1080/14728222.2026.2708824

Wanvisa Udomsinprasert

{"title":"Hepatic T-cell dysfunction in chronic liver disease and hepatocellular carcinoma: a spatial systems-immunology framework for precision immunotherapy.","authors":"Wanvisa Udomsinprasert","doi":"10.1080/14728222.2026.2708824","DOIUrl":"10.1080/14728222.2026.2708824","url":null,"abstract":"Background: Chronic liver diseases, including chronic viral hepatitis, metabolic dysfunction-associated steatohepatitis (MASH), cirrhosis, and hepatocellular carcinoma (HCC), are characterized by progressive immune dysregulation driving chronic inflammation, fibrosis, and hepatocarcinogenesis. Despite hepatic T-cell dysfunction being a defining characteristic of these conditions, it is primarily examined through discrete molecular pathways instead of as an integrated component of the hepatic immune system. This reductionist perspective has limited mechanistic understanding and the development of durable immunotherapeutic strategies.Areas covered: This review proposes a spatial systems-immunology framework as its central conceptual contribution. The framework explains hepatic T-cell dysfunction as an emergent systems-level state arising from coordinated interactions among immune, metabolic, stromal, vascular, and spatial regulatory programs. The translational implications of this framework for biomarker-guided precision immunotherapy in chronic liver disease and HCC are further discussed.Expert opinion: Future advances in liver immunotherapy should prioritize mechanism-based combination therapies guided by multidimensional immune, metabolic, stromal, and spatial biomarkers rather than the ongoing optimisation of individual molecular targets. In this review, it is argued that the proposed spatial systems-immunology framework provides a practical foundation for this transition and may improve patient stratification, therapeutic durability, and long-term clinical outcomes in chronic liver disease and HCC.","PeriodicalId":12185,"journal":{"name":"Expert Opinion on Therapeutic Targets","volume":" ","pages":"853-871"},"PeriodicalIF":5.1,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148618972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Lysophosphatidic acid receptor 5: an emerging therapeutic target for pain. 溶血磷脂酸受体5：一个新兴的疼痛治疗靶点。

IF 5.1 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2026-08-01 Epub Date: 2026-07-28 DOI: 10.1080/14728222.2026.2709795

Olatunbosun Adeoke, Jun-Xu Li

引用次数: 0

The PDPK1-RSK2 axis as a potential convergent therapeutic vulnerability in B-cell lymphomas. PDPK1-RSK2轴作为b细胞淋巴瘤的潜在会聚治疗易感性。

IF 5.1 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2026-08-01 Epub Date: 2026-07-25 DOI: 10.1080/14728222.2026.2709802

Junya Kuroda, Taku Tsukamoto, Yuji Shimura

{"title":"The PDPK1-RSK2 axis as a potential convergent therapeutic vulnerability in B-cell lymphomas.","authors":"Junya Kuroda, Taku Tsukamoto, Yuji Shimura","doi":"10.1080/14728222.2026.2709802","DOIUrl":"10.1080/14728222.2026.2709802","url":null,"abstract":"Introduction: B-cell lymphomas (BCLs) are the most prevalent group of hematologic cancers, encompassing various subtypes, each with a distinct clinical course shaped by cell of origin, genetics, and etiology. Recent advances in subtype-specific immunochemotherapy, targeted therapies, and cellular immunotherapy have improved outcomes for BCLs; nonetheless, some cases remain resistant to existing treatments. To address these resistant disease states, especially across multiple subtypes, the development of new universal targeted therapies could be transformative.Areas covered: This review first highlights what distinguishes the PDPK1/RSK2 signaling axis, outlines its normal biological functions, and briefly examines its roles in solid tumors. It then narrows the focus to BCLs, supported by evidence from our research on pathway activation, functional dependence, prognostic value, and early-stage drug development.Expert opinion: The PDPK1/RSK2 axis is activated in nearly all BCL subtypes and likely plays a significant role in disease development. This suggests the potential for treatments that work across subtypes, despite their genetic and phenotypic differences. Targeting a shared signaling pathway might help overcome resistance seen with traditional precision medicine and support the development of new therapies for rare disease subtypes. However, because current research remains preclinical, more work is necessary.","PeriodicalId":12185,"journal":{"name":"Expert Opinion on Therapeutic Targets","volume":" ","pages":"873-883"},"PeriodicalIF":5.1,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148561196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The therapy-induced senescence-associated secretory phenotype and epithelial-mesenchymal transition axis in ovarian cancer: molecular mechanisms and therapeutic opportunities. 卵巢癌治疗诱导的衰老相关分泌表型和上皮-间质转化轴：分子机制和治疗机会。

IF 5.1 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2026-08-01 Epub Date: 2026-07-30 DOI: 10.1080/14728222.2026.2709798

Ruiqi Wang, Dongsheng Shang, Zhigang Tu, Hanqing Liu

{"title":"The therapy-induced senescence-associated secretory phenotype and epithelial-mesenchymal transition axis in ovarian cancer: molecular mechanisms and therapeutic opportunities.","authors":"Ruiqi Wang, Dongsheng Shang, Zhigang Tu, Hanqing Liu","doi":"10.1080/14728222.2026.2709798","DOIUrl":"10.1080/14728222.2026.2709798","url":null,"abstract":"Introduction: Therapy-induced senescence (TIS) is an important response to anticancer treatments in ovarian cancer, which can trigger the senescence-associated secretory phenotype (SASP) that may contribute to epithelial-mesenchymal transition (EMT), tumor migration, invasion, and adhesion. This review delineates the molecular mechanisms through linking TIS-mediated SASP to EMT and evaluates emerging therapeutic opportunities.Areas covered: We discuss key regulatory pathways including cGAS-STING, NF-κB, p53, and STAT3 that orchestrate SASP components such as IL-6, IL-8, and TGF-β to activate EMT transcription factors. Bioinformatics analyses of clinical datasets identify SASP factors (IL-6, AREG, c-JUN, TIMP1, THBS1) as critical EMT mediators, with hub genes including COL4A2, COL5A2, PDGFRB, and FBN1 involved in ECM remodeling and cell adhesion. SASP promotes ovarian cancer cell adhesion through MMP-mediated ECM degradation, release of matrix-bound growth factors, generation of adhesive fragments, and induction of mesothelial-mesenchymal transition. We evaluate emerging therapeutic strategies targeting this axis, including senolytics to eliminate senescent cells, senomorphics to suppress SASP secretion, and targeted inhibition of specific SASP components.Expert opinion: Although preclinical advances are promising, challenges in model systems and real-time SASP monitoring remain; future integrated multi-omics analyses and personalized therapeutic approaches are needed to translate these findings into improved ovarian cancer outcomes.","PeriodicalId":12185,"journal":{"name":"Expert Opinion on Therapeutic Targets","volume":" ","pages":"885-902"},"PeriodicalIF":5.1,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148619025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0